The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.

In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought ...

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with ...

While patients in Novo trials don't need to take any action, the company recommends patients "remain vigilant and report to ...

Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue ...

Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become ...

With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries are calling for ...

Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker approved since 2021 to treat ...

Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...

Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the ...

Madrigal Pharmaceuticals has installed a 20-foot-tall, 41-foot-wide inflatable liver in a Philadelphia park to mark Global ...

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...